Vertex Pharmaceuticals Incorporated (FRA:VX1)

Market Cap	86.39B
Revenue (ttm)	9.72B
Net Income (ttm)	3.10B
Shares Out	n/a
EPS (ttm)	11.98
PE Ratio	27.89
Forward PE	20.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	142
Average Volume	22
Open	335.60
Previous Close	332.70
Day's Range	330.45 - 337.35
52-Week Range	313.75 - 487.00
Beta	n/a
RSI	55.10
Earnings Date	Nov 3, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VX1

Financial Performance

Financial numbers in USD